Health
AstraZeneca’s COVID-19 vaccine candidate begins late-stage U.S. study – Reuters India
AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
By Reuters Staff
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo
(Reuters) – AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, …
-
Noosa News16 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business17 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Business21 hours agoDividends from ASX 200 bank shares ‘looking very stretched’: expert
-
Noosa News20 hours agoMan who allegedly stole children’s underwear charged with 28 offences